|
Antibacterial Therapies Drug Development Pipeline Review, 2017 |
Mar 23 2017 |
418 |
Global |
$3,995.00 |
|
|
Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence |
May 1 2018 |
215 |
Asia Pacific |
$4,995.00 |
|
|
Cardiovascular Disorders Drug Development Pipeline Review, 2017 |
Mar 16 2017 |
432 |
Global |
$3,995.00 |
|
|
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 |
Apr 1 2018 |
376 |
Global |
$3,995.00 |
|
|
Cosmeceuticals: Global Trends in Market Entry Strategies, Regulatory Framework, Next-Generation Products and Technologies |
Feb 1 2018 |
106 |
Global |
$2,995.00 |
|
|
Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need |
Aug 1 2017 |
79 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms |
May 1 2018 |
68 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease |
Apr 1 2018 |
77 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Women’s Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline |
Feb 1 2018 |
86 |
Global |
$6,995.00 |
|
|
Fungal Foot Infections Drug Development Pipeline Review, 2018 |
Mar 22 2018 |
58 |
Global |
$3,995.00 |
|
|
Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis |
Jan 1 2018 |
79 |
Global |
$2,995.00 |
|
|
Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape |
Dec 1 2017 |
228 |
Global |
$4,995.00 |
|
|
Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis |
Jul 1 2017 |
136 |
Global |
$4,995.00 |
|
|
Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth |
May 1 2017 |
140 |
Global |
$4,995.00 |
|
|
Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs |
Mar 31 2018 |
181 |
Global |
$4,995.00 |
|
|
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential |
Feb 7 2018 |
199 |
Global |
$4,995.00 |
|
|
Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape |
Aug 1 2017 |
132 |
Global |
$4,995.00 |
|
|
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market |
Mar 1 2017 |
197 |
Global |
$4,995.00 |
|
|
HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies |
Mar 31 2018 |
92 |
Asia Pacific |
$4,995.00 |
|
|
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs |
May 1 2016 |
60 |
Global |
$2,995.00 |
|
|
Inflammatory Skin Diseases Drug Development Pipeline Review, 2018 |
May 22 2018 |
112 |
Global |
$3,995.00 |
|
|
Influenza A Viral Infections Drug Development Pipeline Review, 2018 |
Apr 30 2018 |
188 |
Global |
$3,995.00 |
|
|
Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline |
May 1 2017 |
69 |
Global |
$2,995.00 |
|
|
Mosquito-borne Diseases Drug Development Pipeline Review, 2018 |
May 24 2018 |
142 |
Global |
$3,995.00 |
|
|
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 |
Mar 21 2017 |
797 |
Global |
$3,995.00 |
|
|
Pharmaceutical Lifecycle Management Strategies in 2017 |
Apr 1 2017 |
82 |
Global |
$2,995.00 |
|
|
Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market |
Jun 1 2018 |
125 |
Asia Pacific |
$4,995.00 |
|
|
Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018 |
Apr 30 2018 |
82 |
Global |
$3,995.00 |
|
|
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs |
Mar 1 2018 |
148 |
Asia Pacific |
$4,995.00 |
|
|
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects |
Dec 14 2015 |
67 |
Global |
$2,995.00 |
|
